Evidence map›Paper›PMID 35434784›Full record

ArticleDiabetic medicine : a journal of the British Diabetic Association2022

Selecting a target population for type 2 diabetes lifestyle prevention programs: A cost-effectiveness perspective.

Joohyun Park, Ping Zhang, Hui Shao, Michael Laxy, Giuseppina Imperatore

Abstract read
In one paragraph

Article in Diabetic medicine : a journal of the British Diabetic Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Joohyun ParkDivision of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Ping ZhangDivision of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Hui ShaoCollege of Pharmacy, University of Florida, Gainesville, Florida, USA.
Michael LaxyInstitute of Health Economics and Health Care Management, Helmholtz Zentrum München GmbH, Neuherberg, Germany.
Giuseppina ImperatoreDivision of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

aimsCost-effectiveness (CE) of lifestyle change programs (LCP) for type 2 diabetes (T2D) prevention is influenced by a participant's risk. We identified the risk threshold of developing T2D in the intervention population that was cost-effective for three formats of the LCP: delivered in-person individually or in groups, or delivered virtually. We compared the cost-effectiveness across program formats when there were more than one cost-effective formats.

methodsUsing the CDC-RTI T2D CE Simulation model, we estimated CEs associated with 3 program formats in 8 population groups with an annual T2D incidence of 1% to 8%. We generated a nationally representative simulation population for each risk level using the 2011-2016 National Health and Nutrition Examination Survey data. We used an incremental cost-effectiveness ratio (ICER), cost per quality-adjusted life year (QALY) gained in 25-years, to measure the CEs of the programs. We took a health care system perspective.

resultsTo achieve an ICER of $50,000/QALY or lower, the annual T2D incidence of the program participant needed to be ≥5% for the in-person individual program, ≥4% for the digital individual program, and ≥3% for the in-person group program. For those with T2D risk of ≥4%, the in-person group program always dominated the digital individual program. The in-person individual program was cost-effective compared with the in-person group program only among persons with T2D risk of ≥8%.

conclusionsOur findings could assist decision-makers in selecting the most appropriate target population for different formats of lifestyle intervention programs to prevent T2D.

Indexed as

Diabetes Mellitus, Type 2Cost-Benefit AnalysisHumansLife StyleNutrition SurveysQuality-Adjusted Life Yearscost-effectivenesslifestyle change programpreventiontype 2 diabetes

Identifiers

PMID35434784
PMCPMC9578149

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.